Chengdu Easton Biopharmaceuticals Co., Ltd. Class ASSE: 688513

Announcement on Voluntary Disclosure of the First Subject Dosing in the Phase I Clinical Trial of EP-0210 Monoclonal Antibody Injection

· Issued by Chengdu Easton Biopharmaceuticals Co., Ltd. Class A via Shanghai Stock Exchange
Announcement on Voluntary Disclosure of the First Subject Dosing in the Phase I Clinical Trial of EP-0210 Monoclonal Antibody Injection

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference: View Attachment

Company analysis